Highest-materiality recent filing
BriaCell closes $4.7M best-efforts equity offering; 1.45M shares at $3.25 each
Gross proceeds ~$4.7M from sale of 1,449,300 common shares at $3.25/share in a best-efforts offering.
BriaPro subsidiary reports $472K net loss for six months; going concern risk
BriaPro net loss widened to $472,231 for six months ended Jan 31, 2026 vs $233,185 a year ago.
BriaCell transfers exclusive license for Soluble CD80 to BriaPro for 23,972,589 BriaPro shares, increasing stake to ~78%.
BriaCell closes $30M public offering of units; warrants trade under BCTXL
Closed public offering of 5,366,726 units at $5.59/unit for gross proceeds of ~$30M.
BriaPro subsidiary posts Q1 operating loss $258K, R&D spend jumps 5x, going concern doubt
Net loss $244,738 for three months ended Oct 31, 2025, vs $82,123 prior year; operating loss $258,445.
BriaPro subsidiary reports $740K loss; going concern doubt flagged by auditor
BriaPro net loss $740,216 for year ended July 31, 2025, accumulated deficit $1,180,425.
BriaCell closes $15M public offering of 12M units at $1.25/unit
Gross proceeds of $15M before fees; 12,000,000 units sold at $1.25 per unit.
BriaPro Therapeutics (2/3 owned by BriaCell) reports net loss of $519,804 for 9 months, cash only $1
Net loss of $519,804 for nine months ended April 30, 2025 vs. $316,517 in prior year period.
BriaCell closes $13.8M public offering of units with warrants
Gross proceeds of ~$13.8M from 3,066,666 units at $4.50/unit, including 399,999 from over-allotment
Net loss for six months ended Jan 31, 2025: $233,185; accumulated deficit $673,394.
BriaCell regains Nasdaq minimum bid price compliance; delisting risk resolved
Received Nasdaq notice of compliance with $1.00 minimum bid price requirement on Feb 12, 2025.
BriaCell closes $5.55M public offering of 7.4M units at $0.75/unit
Underwritten public offering of 7,400,000 units closed Dec 13, 2024; gross proceeds $5.55M.
BriaCell closes $5M offering of 5.1M shares and warrants at $0.975/unit
5,128,500 common shares and warrants to purchase 5,128,500 common shares sold at $0.975 per unit.
Patient with 'eye-bulging' orbital tumor and brain metastasis achieved complete resolution of temporal lobe lesion at 8 and 11 months on Bria-IMT plus checkpoint inhibitor.
BriaCell closes $8.5M public offering of 12.3M shares at $0.69 each
Gross proceeds of $8,504,250 from sale of 12,325,000 common shares at $0.69/share.
BriaCell reports median OS of 15.6 months in Phase 2 Bria-IMT study; FDA path cleared for Bria-PROS+
Median overall survival of 15.6 months in 25 patients receiving Phase 3 Bria-IMT formulation vs 6.7–9.3 months in literature controls.
Received Nasdaq deficiency letter on Aug 22, 2024; bid price below $1.00 for 30 consecutive business days.
BriaCell Quadruples PFS to 9.1 Months in Top Responder Metastatic Breast Cancer Patient
PFS extended to 9.1 months in top responder patient, quadruple historical controls (1.7-2.3 months).
BriaCell receives Nasdaq notice for failing $35M minimum MVLS requirement
Received Nasdaq letter on July 3, 2024, for MVLS below $35M for 33 consecutive business days.
BriaPro subsidiary reports $317K net loss, $1 cash, going concern doubt
Net loss of $316,517 for nine months ended April 30, 2024; zero revenue.
BriaCell raises $5.0M in registered direct offering with warrants; director participates
Gross proceeds of $5.0M from sale of 2,402,935 shares (or pre-funded warrants) and warrants for additional 2,402,935 shares.
On November 23, 2024, Marc Lustig resigned from the board of directors of BriaCell Therapeutics Corp. (the “Company”)
Max materiality 0.80 · Median 0.62 · Most common event other_material